Biorasi’s podcast – Few & Far Between: Conversations from the Front Lines of Drug Development – was created to spark discussions on trending topics and innovations across the clinical research industry. Hosted by Chris O’Brien, CEO, each episode features cutting edge conversations with biotech leaders and industry experts. Follow us on LinkedIn and social media to be the first to know when new episodes launch. You can listen to our episodes on Apple podcasts, your favorite streaming platforms, or by clicking on the links below. If you’re enjoying the podcast, please consider leaving us a review on Apple Podcasts.
Our latest episodes can be found here.
- Episode 46: Ben Olds and Amy Fenollosa, Haven Human Asset Ventures
- Episode 47 – Marc Lajoie, CEO at Outpace Bio
- Episode 45: Dr. Carsten Rudolph, CEO and Managing Director at Ethris
- Episode 44: Jonathan Scheiman, PhD, Co-Founder and CEO at FitBiomics
- Episode 43: Isaac Stoner, Co-founder and CEO at Octagon Therapeutics
- Episode 42: Diana Azzam, PhD, Assistant Professor at Florida International University, Co-Founder at First Ascent Biomedical
- Episode 41: Craig Serra, Head of Clinical Research, Scientific, and Technical Engagement, Flatiron Health
- Episode 40: Professor Justin Stebbing, Editor-in-Chief, Oncogene journal
- Episode 39: Dr. Keith Flaherty, Director of Clinical Research at Massachusetts General Hospital Cancer Center
- Episode 38: Dr. Ole Isacson, Professor of Neurology and Neuroscience, Harvard Medical School
- Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche
- Episode 36: Zak Kohane, Department of Biomedical Informatics at Harvard Medical School
- Episode 35: Charlene Son Rigby, CEO at Global Genes
- 34: Dan Mandell, CEO at GRO Biosciences
- Episode 33: Diana Sims-Silbermann, Clinician and Former Senior Trial Manager at Janssen Pharmaceuticals
- Episode 32: Stephanie Wisner, Author, Co-Founder at Centivax
- Episode 31: Pam Cusick, SVP, Rare Patient Voice
- Episode 30, Part Two: Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH
- Episode 30, Part One: Dr. Francisco Harrison, CEO and owner, Harrison CST Holding GmbH
- Episode 29: Mika Newton, CEO at XCures
- Episode 28: Dr. Alok Tayi, Founder and CEO of VibeBio
- Episode 27, Part 2: Jamie Heywood, Biotech Engineer and Entrepreneur
- Episode 27, Part 1: Jamie Heywood, Biotech Engineer and Entrepreneur
- Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
- Episode 25: Jim Geraghty, Author and Biotech Industry Veteran
- Episode 24: Gadi Lachman, President and CEO, TriNetX
- Episode 23: Dr. Arun Bhatt, Consultant for Clinical Research and Drug Development in India
- Episode 22: Dr. Jocelynn Pearl, Senior Scientist at Tune Therapeutics, Host of Lady Scientist Podcast
- Episode 21: Jill Hawkins, Founder and President of the FAM177A1 Research Fund
- Episode 20: Professor Bertil E. Lindmark MD, PhD, Author and CMO at Galecto, Inc.
- Episode 19: Leslie Michelson, Founder and CEO, Private Health Management
- Episode 19: Leslie Michelson, Founder and CEO, Private Health Management
- Episode 18: Karen Petrou and David Brint – BioBonds
- Episode 17: Amy Fenton Parker, President and CEO at Batten Disease Support and Research Organization (BDSRA)
- Episode 16: Dr. Alex Adjei, Scientific Advisory Board Member at Biorasi
- Episode 15: Dr. Terry Jo Bichell, Founder and Director of COMBINEDBrain
- Episode 14: Bo Bigelow, Chairman at the Foundation for USP7-Related Diseases, and Trish Flanagan, President at the Yellow Brick Road Project
- Episode 13: Kelly Franchetti RN, SVP, Global Head Patient Insights and Strategy at YPrime
- Episode 12: Effie Parks and Spela Mirosevic
- Episode 11: Rebecca Stewart and Nicola Miller from Rare Revolution Magazine
- Episode 10: Sharon Terry, CEO Genetic Alliance
- Episode 9: Zogenix, Inc.'s Dawn Blessing and J. Michael Graglia from SynGAP
- Episode 8: David Rose, Rare Disease Speaker and Advocate
- Episode 7: US Congressman Gus Bilirakis
- Episode 6: Dr. Mehool Patel and Dr. Dilhan Weeraratne, IBM Watson Health
- Episode 5: Will Maier, VP of Rare Disease, Drug Development Sciences at ICON plc
- Episode 4: Marianne Clancy, Executive Director at Cure HHT
- Episode 3: Danielle Drayton, PhD, CEO of REACH Market Research
- Episode 2: Julie Walters, Founder and Executive Director of Xperiome/Raremark
- Episode 1: Paula Evans, CEO and Co-Founder of GeneTx Biotherapeutics
- Episode 0: Welcome to the Few & Far Between Podcast
